Featuring William Donnellan, MD, Sarah Cannon, this webinar will highlight stand-out abstracts presented at the latest ASH Annual Meeting. Participants will learn about exciting research developments in hematology-oncology and discover how these updates may be translated into cutting-edge patient care.
Guest Speaker: William Donnellan, MD
Director, Acute Leukemia/Myelodysplastic Syndromes Research
Sarah Cannon Research Institute/Tennessee Oncology
Dr. Donnellan joined Sarah Cannon in 2014 as an investigator of hematologic malignancies with expertise in treating patients with a variety of blood cancers—specifically myeloid stem cell disorders including the myelodysplastic syndromes, acute myeloid leukemia, and the myeloproliferative neoplasms.
In his current role, Dr. Donnellan oversees research surrounding myeloid stem cell disorders for the Sarah Cannon program in Nashville and Sarah Cannon Blood Cancer Network. The Sarah Cannon Blood Cancer Network is one of the largest providers of hematopoietic cell transplantation, and conducts more than 1,000 transplants annually through six FACT-accredited transplant centers.
Dr. Donnellan is board certified in internal medicine, hematology and medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.